Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
13,155,511
-
Total 13F shares
-
87,507
-
Share change
-
+64,537
-
Total reported value
-
$1,897,924
-
Price per share
-
$21.75
-
Number of holders
-
18
-
Value change
-
+$1,405,693
-
Number of buys
-
10
-
Number of sells
-
6
Institutional Holders of Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) as of Q1 2024
As of 31 Mar 2024,
Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) was held by
18 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
87,507 shares.
The largest 10 holders included
Ikarian Capital, LLC, Sio Capital Management, LLC, Affinity Asset Advisors, LLC, UBS Group AG, ADAR1 Capital Management, LLC, NATIXIS, BlackRock Inc., Tower Research Capital LLC (TRC), Banque Cantonale Vaudoise, and Royal Bank of Canada.
This page lists
18
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.